A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia.

Trial Profile

A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Aug 2012 Actual initiation date (14 Jan 2009) added as reported by European Clinical Trials Database.
    • 17 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment, as reported by clinicaltrials.gov.
    • 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top